Introduction and Background
Mullaways Medical Cannabis Pty Ltd (Mullaways) is a federally registered company under Australian law, and has been since the 21st of October 2008. Mullaways is the first medical cannabis company established and registered in Australia for the purpose of scientific research, cannabis education and the development and delivery of medicines derived from cannabis/cannabinoids for the management of chronic pain, nausea and appetite.
Mullaways first natural cannabinoid based medicine, MULLAWAYS CANNABINOID TINCTURE was designed to be an alternative delivery method for cannabinoids to the traditional method of smoking cannabis. It was also designed to assist with the regulation of Anandamide in the human body. There is evidence that Anandamide can serve as a neuromodulator or neurotransmitter on its own or in conjunction with inactive precursors in what has been dubbed the "entourage effect".
There are currently no cannabinoid medicines registered in Australia on the Australian Register of Therapeutic Goods (ARTG).
Mullaways is at the forefront of medical cannabinoid research and development of cannabinoid medicines in Australia.
Mullaways once issued a license/exemption, granting authorisation - to cultivate, possess and supply cannabis/cannabis plants for the purposes of scientific research, analysis and study pursuant to the Drugs Misuse and Trafficking Act 1985 (NSW) - will then be in a position to proceed to human clinical trials and for MULLAWAYS CANNABINOID TINCTURE to be registered as a medicine on the ARTG.
Mullaways has endeavoured to undertake all necessary steps to bring its medical cannabis company and Cannabinoid Tincture within a legal framework. Mullaways is prepared to take any further steps deemed necessary by NSW Health to ensure that all legal requirements are met and is willing to comply with any conditions imposed by NSW Health to ensure the security of the medical cannabis.
Aims and Objectives
Mullaways objective is to establish a quality assured medical cannabinoid manufacturing business large enough to service the mass numbers of seriously ill for whom orthodox medicines have not been of any aid... to have the capacity to quickly respond to extreme growth spurts in demand... to grow to an international capacity servicing Australia as well as exporting and setting up services and facilities overseas.
Mullaways is dedicated to the development of cannabinoid based medicines both with and without psychoactive properties to treat disease; the symptoms of disease and for general health maintenance. Mullaways will adhere to scientific methodologies to develop, produce, and commercialise cannabinoid-based traditional medicines.
Mullaways has cross bred different types of the cannabis plants to produce new strains that can be used to develop more effective medicines to treat particular medical conditions.
Mullaways requires authorisation to evaluate its first cannabinoid medicine, MULLAWAYS CANNABINOID TINCTURE for its quality, safety and efficacy pursuant to provisions of the Therapeutic Goods Act with the aim of ensuring that medical cannabis patients in Australia have access, within a reasonable time, to a therapeutic cannabinoid based medicine of an acceptable standard that may be delivered more safely and effectively than by smoking cannabis. (Note: The dosage of THC in the MULLAWAYS CANNABINOD TINCTURE is so low; the Tincture is in-fact not illegal and the illegality of this medicine simply falls with the cultivation, possession and supply of cannabis plants to produce said medicine.)
Mullaways first cannabinoid based medicine, MULLAWAYS CANNABINOID TINCTURE will be indicated for symptomatic relief of severe uncontrolled epilepsy, endocannabinoid deficiency/imbalance, pain, nausea, spasticity and neuropathic pain in patients with cancer, AIDS, neurological disorders including (but not limited to) multiple sclerosis, Tourette's syndrome, and motor neurone disease and other conditions that have not responded adequately to other medicines.
These clinical indications are consistent with the Key Findings of the Working Party: Report on the Use of Cannabis for Medical Purposes (2000 Vol 1). The Working Party agreed with the Institute of Medicine and the House of Lords reports on the therapeutic potential of cannabinoids. The report concluded that the medical conditions for which cannabis may be of medical benefit are:
* HIV-related wasting and cancer-related wasting;
* Pain unrelieved by conventional treatments;
* Neurological disorders including (but not limited to) multiple sclerosis, Tourette's syndrome, and motor neurone disease;
* Nausea and vomiting in cancer patients undergoing chemotherapy which does not respond to conventional treatments;
Mullaways proposes to research and develop other cannabinoid based medicines including patches, creams, oils and edibles that have therapeutic benefits and that may be delivered more safely and effectively than by smoking cannabis.
Mullaways also proposes to conduct research into the different methods of growing the cannabis plant and conduct research into the basic chemistry and pharmacology of cannabinoids with the aim of developing cannabinoid based medicines of an acceptable standard that may be delivered more safely and effectively than by smoking cannabis.
At least 1 in 5 Australians, that's including children, live with chronic pain. Among people aged over 65, it's 1 in 3. Research shows that chronic pain left untreated leads to devastating effects on the welfare of people's lives, and the longer this goes on untreated the worse it gets. The National Pain Strategy, developed by more than 150 healthcare professionals and consumers at a 2010 national summit, recommended chronic pain be recognised as a priority health issue and constitute a disease in its own right. Yet it remains one of the most neglected areas of healthcare.
Rare disease affects more than 2 million Australians and are defined as a condition, syndrome or disorder that affects 1 in 10,000 people or less and are either life-threatening or chronically debilitating. Many are alone in their plight to tackle and come to terms with an incredibly unique, debilitating and life-threatening illness.
At this current time Austria, Belgium, Canada, Chile, Czech Republic, Finland, Germany, Israel, Italy, Mexico, the Netherlands, New Zealand, Portugal, Spain, Switzerland, the UK, and 19 U.S. States (Alaska, Arizona, California, Colorado, Connecticut, Hawaii, Maine, Maryland, Massachusetts, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Washington, and Washington DC) have all started loosening thier laws to varying degrees to provide regulated and/or legalised cannabis based medicines if prescribed by a licensed medical practitioner to a patient for nausea, pain or the alleviation of symptoms surrounding chronic illness.
This reflects the increasing recognition of the benefits of cannabis use to medicate for certain illnesses.
In the Australian 2010 National Drug Strategy Household Survey Report 68.8% of people aged over 14 years supported the legalisation of medical cannabis, and 74% supported clinical trials. A preliminary survey of general practitioners in the NSW northern rivers region indicated that Doctors have similar opinions, with 75% indicating they would prescribe cannabis if it were legal and supported by clinical research, and 100% of participants supportive of a trial.
Mullaways believes its time NSW and Australia joins the majority of the other Developed Nations in the 21st century.
The establishment of a medical cannabis industry in NSW and Australia under adequate Government supervision would produce thousands of jobs for Australian citizens, and provide safe, quality medicine for many more thousands in need.